CMB-012

N/A

Report date: 2025/12/12 11:02:46

Base Information

Drug NameCMB-012
Drug Alias NameHuman mesenchymal stem cell secretome (MSC-S) therapy（Kala）CMB-012KPI-012
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionGrowth factor receptors agonistsProtease inhibitorsPeptide hydrolase replacements +[4] 
TargetsGrowth factor receptorsProtease
Therapy Area/IndicationsPersistent corneal epithelial defectLimbal Stem Cell DeficiencyRare Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoArgentina
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCombangio IncKala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesKala Pharmaceuticals Inc
Inactive CompaniesCombangio Inc
Active IndicationsLimbal Stem Cell DeficiencyRare Diseases
Inactive IndicationsPersistent corneal epithelial defect

Other Information

ATC CodeN/A
Related LinksN/A